Ludwig Prepares Major Patent Filing
SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to announce that the Company has started discussions with Emerson Urology Associates, Concord, MA regarding initiation of a clinical study to evaluate the response of bladder cancer patients to BCG immunotherapy. A confidentiality agreement has been signed with Dr. John Libertino, MD, Director of Emerson Urology Associates.
Bladder cancer is the sixth most common cancer in the United States and the ninth most common worldwide. Cancers of the bladder make up about 5% of new U.S. cancer cases each year, mostly in older people. In 2021, there will be an estimated 83,000 new cases diagnosed and approximately 17,000 deaths in the U.S. alone. Standard treatment for patients with bladder cancer that has invaded muscle tissue includes cisplatin-based chemotherapy followed by surgical removal of the bladder or radiation therapy and concomitant chemotherapy.
An additional treatment approach is an immunotherapy, a class of treatments that uses a person's own immune system to help kill cancer cells. Bacillus Calmette-Guérin (BCG) is a cancer vaccine that uses weakened bacteria to stimulate the immune system. BCG has received U.S. FDA approval for the treatment of early-stage bladder cancer.
The objective of the joint research program between Ludwig Enterprises and Emerson Urology Associates is to use Ludwig's proprietary genetic inflammatory markers to study patients with early-stage superficial bladder cancer and assess therapeutic response to BCG immunotherapy.
Ludwig's proprietary genetic inflammatory biomarker panel is in the process of being submitted to the U.S. Patent office.
'This innovative research study has the potential to create a predictive model of early-stage cancer occurrence at a presymptomatic stage and show which patients will respond to specific anticancer chemotherapy,' stated Dr. Marvin S. Hausman MD, Chairman of Ludwig's Scientific Advisory Board (SAB). 'In essence, Ludwig has developed a proprietary language that has the potential to capture a snapshot of disease and the body's response to treatment.'
'Early diagnosis of urologic cancer and ability to predict anticancer response has been a dream of mine for a long time,' said Dr. John Libertino, MD, Director of Emerson Urology Associates.' I am looking forward to seeing the clinical results from this collaborative relationship.'
About Ludwig Enterprises, Inc.: Ludwig is an innovative technology and health-related company that uses inflammatory genetic markers to diagnose disease, diagnose, and assess pre- and post-treatment responses. Initial clinical programs will include but not be limited to cardiac disease, preeclampsia, breast cancer, colon cancer, and bladder cancer.
About Emerson Urology Associates: Our Urologists provide comprehensive medical and surgical services for urologic conditions, offering today's most advanced diagnostic and treatment expertise.
Forward-looking statements in this release are made under the 'safe harbor' provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements are not a guarantee of future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
SOURCE: Ludwig Enterprises, Inc.
View source version on accesswire.com: